Drugs approved since legislation to speed up the approval process at the US Food and Drug Administration are more likely to have received black box warnings or been withdrawn from the market, according to a new analysis appearing in Health Affairs.
Registering provides access to this and other free content.
Already have an account?Login Now.
In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.
At Nature, John Wilbanks and Eric Topol call for openness in health data.
Law.com predicts that genomic and genetic testing will become common in toxic tort cases.
A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.